2Williamson JD,Launer LJ,Bryan RN,et al.Cognitivefunction and brain structure in persons with type 2 diabetesmellitus after intensive lowering of blood pressure and lipidlevels:A randomized clinical trial [J].JAMA Intern Med,2014,174(5):812-813. 被引量：1
3Gallwitz B.Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus:current emergine agents[J].Drugs,2011,71(13):1675-1688. 被引量：1
5Nikfar S,Abdollahi M,Salari P.The efficacy and tolerabolity of exenatide in comparison to placebo:a systematic review and meta-analysis of randomized clinical trials[J].J Pharm Pharm Sci,2012,15(1):1-30. 被引量：1
2Bagger JI,Knop FK, Lund A, et al. Impaired regulation of the incretineffect in patients with type 2 diabetes [ J ]. J Clin Endocrinol Metab,2011,96(3) :737-745. 被引量：1
3Bunck MC, Diamant M, Comer A, et al. Oen-year treatment with ex-enatide improves p-cell function, compared with insulin glargine, in met-formin-treated type 2 diabetic patients : a randomized, controlledtrial. Di-abetes Care,2009,32(5) :762-768. 被引量：1
4Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide ( ex-endin-4) on glycemic control and weight over 30 weeks in patients withtype 2 diabetes treated with metformin and a sulfonylurea[ J] . DiabetesCare ,2005,28(5): 1083-1091. 被引量：1
5Garber A,Henry R,Ratner R, et al. Liraglutide versus glimepiridemonotherapy for type 2 diabetes ( LEAD-3 Mono) : a randomised,52-week,phase III,double-blind,parallel-treatment trial[ J]. Lancet,2009,373(9662):473481. 被引量：1
